logo
Plus   Neg
Share
Email

IMMY Turning Heads, HSM Awaits Phase 3 Data This Year, LQDA On Watch

pharmaup-nov14-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. Imprimis Pharmaceuticals Inc. (IMMY)

Gained 19.43% to close Wednesday's (Nov.14) trading at $4.61.

News: The Company reported a narrower loss on 66% revenue growth.

Net loss for the third quarter ended September 30, 2018 narrowed to $2.51 million or $0.12 per share from $5.69 million or $0.28 per share in the year-ago quarter. Revenue for the recent quarter climbed to $10.74 million from $6.48 million in the year-earlier quarter.

IMMY was trading around $3.72 when we alerted readers to this stock on October 25, 2018. The stock touched a high of $4.74 in intraday trading today, before closing at $4.61, up 19.43%.

Related Reading

Eyes On Imprimis...

2. Hutchison China MediTech Limited (HCM)

Gained 17.23% to close Wednesday's trading at $37.69.

News: No news

Near-term Catalysts:

-- Report top-line results from phase III study of Fruquintinib for non-small cell lung cancer in China in late 2018.
-- Approval of Fruquintinib in China for colorectal cancer this year.
-- Interim analysis of phase III study of Fruquintinib for second-line gastric cancer in China in 2019.

3. Diversicare Healthcare Services Inc. (DVCR)

Diversicare is provider of post-acute care, offering a range of services from short term rehabilitation for individuals recovering from an injury or illness, to longer term care like providing memory care programs.

Gained 17.18% to close Wednesday's trading at $4.94.

News: No news

4. Liquidia Technologies Inc. (LQDA)

Gained 14.65% to close Wednesday's trading at $22.15.

News: The Company has been awarded the best-in-class Public Offering Award at the 20th annual SEBIO Investor and Partnering Forum.

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development of two product candidates for the treatment of pulmonary arterial hypertension and local post-operative pain.

The Company went public on the Nasdaq Capital Market on July 26, 2018, offering its shares at a price of $11 each.

Pipeline:

The lead drug candidate is LIQ861 for the treatment of pulmonary arterial hypertension, or PAH.

LIQ861 is under a phase III trial, dubbed INSPIRE. This trial, initiated in January of this year, is designed to enroll at least 100 patients with PAH across multiple U.S. sites. Safety data from INSPIRE are expected in the first half of 2019.

LIQ865 for the treatment of local post-operative pain, which completed a Phase 1a clinical trial in Denmark in March 2017, and a Phase 1b clinical trial in the United States in April 2018.

Near-term Catalysts:

-- The safety, pharmacokinetics and pharmacodynamic results from its Phase 1a study in healthy volunteers of LIQ865 are scheduled to be presented on November 16, 2018.
-- Initiate Phase 2-enabling toxicology studies for LIQ865 for the treatment of local post-operative pain in the fourth quarter of 2018.
-- Two-week safety data readout from phase III trial of LIQ861 (INSPIRE) is anticipated in the first quarter of 2019.

5. Synlogic Inc. (SYBX)

Gained 9.90% to close Wednesday's trading at $8.44.

News: The Company reported a narrower loss on higher revenues for the third quarter ended September 30, 2018, and provided an update on its programs.

For the three months ended September 30, 2018, the consolidated net loss narrowed to $10.7 million, or $0.43 per share from $11.9 million or $1.66 per share for the corresponding period in 2017. Revenues from collaboration agreement were $1.8 million for the recent quarter compared to $0.1 million for the corresponding period in 2017.

Near-term Catalysts:

-- Topline data from phase 1b/2a clinical trial of SYNB1020 in patients with cirrhosis and elevated ammonia are expected in mid-2019.
-- Topline data from phase 1/2a study of SYNB1618 in patients with Phenylketonuria is expected in mid-2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT